Raloxifene- and estradiol-mediated effects on uterus, bone and B lymphocytes in mice

Journal of Endocrinology

Volumn 175, Issue 2, 2002, Pages 319-327

  Erlandsson, M C ^a   Jonsson, C A ^a   Lindberg, M K ^a   Ohlsson, C ^a   Carlsten, H ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

6 HYDROXY 2 (4 HYDROXYPHENYL) 3 [4 [2 (1 PYRROLIDINYL)ETHOXY]BENZOYL]BENZO[B]THIOPHENE; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; IMMUNOGLOBULIN; LIPID; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SOMATOMEDIN C;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; B LYMPHOCYTE; BLOOD VESSEL; BONE DENSITY; BONE MARROW CELL; BONE METABOLISM; BONE MINERAL; BONE TISSUE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG SELECTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESTROGEN ACTIVITY; FEMALE; FLOW CYTOMETRY; IMMUNE SYSTEM; IMMUNOGLOBULIN PRODUCTION; LYMPHOCYTE FUNCTION; LYMPHOPOIESIS; MOUSE; NONHUMAN; OSTEOPOROSIS; OVARIECTOMY; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; RHEUMATIC DISEASE; SPLEEN CELL; UTERUS; UTERUS WEIGHT;

ANIMALS; B-LYMPHOCYTES; BONE AND BONES; ESTRADIOL; FEMALE; FLOW CYTOMETRY; IMMUNOENZYME TECHNIQUES; INSULIN-LIKE GROWTH FACTOR I; LYMPHOPOIESIS; MICE; MICE, INBRED C57BL; PYRROLIDINES; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SPLEEN; THIOPHENES; TOMOGRAPHY, X-RAY COMPUTED; UTERUS;

EID: 13844293153     PISSN: 00220795     EISSN: None     Source Type: Journal    
DOI: 10.1677/joe.0.1750319     Document Type: Review

References (41)

1. Baker VL, Draper M, Paul S, Allerheiligen S, Glant M, Shifren J & Jaffe RB 1998 Reproductive endocrine and endometrial effects of raloxifene hydrochloride, a selective estrogen receptor modulator, in women with regular menstrual cycles. Journal of Clinical Endocrinology and Metabolism 83 6-13.
2. Black LJ, Sato M, Rowley ER, Magee DE, Bekele A, Williams DC, Cullinan GJ, Bendele R, Kauffman RF, Bensch WR et al. 1994 Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. Journal of Clinical Investigation 93 63-69.
3. Blum WF & Breier BH 1994 Radioimmunoassays for IGFs and IGFBPs. Growth Regulation 4 (Suppl) 11-19.
4. Brzozowski AM, Pike AC, Dauter Z, Hubbard RE, Bonn T, Engstrom O, Ohman L, Greene GL, Gustafsson JA & Carlquist M 1997 Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389 753-758.
5. Carlsten H, Tarkowski A, Holmdahl R & Nilsson LA 1990 Oestrogen is a potent disease accelerator in SLE-prone MRL lpr/lpr mice. Clinical and Experimental Immunology 80 467-473.
6. Carlsten H, Verdrengh M & Taube M 1996 Additive effects of suboptimal doses of estrogen and cortisone on the suppression of T lymphocyte dependent inflammatory responses in mice. Inflammation Research 45 26-30.
7. Couse JF, Lindzey J, Grandien K, Gustafsson JA & Korach KS 1997 Tissue distribution and quantitative analysis of estrogen receptor-alpha (ERalpha) and estrogen receptor-beta (ERbeta) messenger ribonucleic acid in the wild-type and ERalpha-knockout mouse. Endocrinology 138 4613-4621.
8. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, Norton L, Nickelsen T, Bjarnason NH, Morrow M et al. 1999 The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple outcomes of raloxifene evaluation. Journal of the American Medical Association 281 2189-2197.
9. Czerkinsky CC, Nilsson LA, Tarkowski A, Ouchterlony O, Jeansson S & Gretzer C 1984 An immunoenzyme procedure for enumerating fibronectin-secreting cells. Journal of Immunoassay 5 291-302.
10. Dahlgren UI & Hanson LA 1991 Effect of oestradiol on the secretory immune system in the rat: an increase in biliary IgM antibodies against a T-cell independent antigen. Immunology 74 74-77.
11. Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, Draper M & Christiansen C 1997 Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. New England Journal of Medicine 337 1641-1647.
12. Erlandsson MC, Gomori E, Taube M & Carlsten H 2000 Effects of raloxifene, a selective estrogen receptor modulator, on thymus, T cell reactivity, and inflammation in mice. Cellular Immunology 205 103-109.
13. Erlandsson MC, Ohlsson C, Gustafsson JA & Carlsten H 2001 Role of oestrogen receptors alpha and beta in immune organ development and in oestrogen-mediated effects on thymus. Immunology 103 17-25.
14. Foster M, Montecino-Rodriguez E, Clark R, & Dorshkind K 1998 Regulation of B and T cell development by anterior pituitary hormones. Cellular and Molecular Life Sciences 54 1076-1082.
15. Hanna N & Schneider M 1983 Enhancement of tumor metastasis and suppression of natural killer cell activity by beta-estradiol treatment. Journal of Immunology 130 974-980.
16. Holmdahl R, Carlsten H, Jansson L & Larsson P 1989 Oestrogen is a potent immunomodulator of murine experimental rheumatoid disease. British Journal of Rheumatology 28 (Suppl) 54-58; discussion 69-71.
17. Josefsson E, Tarkowski A & Carlsten H 1992 Anti-inflammatory properties of estrogen. I. In vivo suppression of leukocyte production in bone marrow and redistribution of peripheral blood neutrophils. Cellular Immunology 142 67-78.
18. Kahlert S, Nuedling S, van Eickels M, Vetter H, Meyer R & Grohe C 2000 Estrogen receptor alpha rapidly activates the IGF-1 receptor pathway. Journal of Biological Chemistry 275 18447-18453.
19. Kleinman D, Karas M, Danilenko M, Arbell A, Roberts CT, LeRoith D, Levy J & Sharoni Y 1996 Stimulation of endometrial cancer cell growth by tamoxifen is associated with increased insulin-like growth factor (IGF)-I induced tyrosine phosphorylation and reduction in IGF binding proteins. Endocrinology 137 1089-1095.
20. Kuiper GG, Shughrue PJ, Merchenthaler I & Gustafsson JA 1998 The estrogen receptor beta subtype: a novel mediator of estrogen action in neuroendocrine systems. Frontiers in Neuroendocrinology, 19 253-286.
21. Lonard DM & Smith CL 2002 Molecular perspectives on selective estrogen receptor modulators (SERMs): progress in understanding their tissue-specific agonist and antagonist actions. Steroids 67 15-24.
22. Manabe N, Kawaguchi H, Chikuda H, Miyaura C, Inada M, Nagai R, Nabeshima Y, Nakamura K, Sinclair AM, Scheuermann RH et al. 2001 Connection between B lymphocyte and osteoclast differentiation pathways. Journal of Immunology 167 2625-2631.
23. Masuzawa T, Miyaura C, Onoe Y, Kusano K, Ohta H, Nozawa S & Suda T 1994 Estrogen deficiency stimulates B lymphopoiesis in mouse bone marrow. Journal of Clinical Investigation 94 1090-1097.
24. Medina KL, Smithson G & Kincade PW 1993 Suppression of B lymphopoiesis during normal pregnancy. Journal of Experimental Medicine 178 1507-1515.
25. Medina KL, Strasser A & Kincade PW 2000 Estrogen influences the differentiation, proliferation, and survival of early B-lineage precursors. Blood 95 2059-2067.
26. Montecino-Rodriguez B, Clark RG, Powell-Braxton L & Dorshkind K 1997 Primary B cell development is impaired in mice with defects of the pituitary/thyroid axis. Journal of Immunology 159 2712-2719.
27. Nilsson N & Carlsten H 1994 Estrogen induces suppression of natural killer cell cytotoxicity and augmentation of polyclonal B cell activation. Cellular Immunology 158 131-139.
28. Onoe Y, Miyaura C, Ohta H, Nozawa S & Suda T 1997 Expression of estrogen receptor beta in rat bone. Endocrinology 138 4509-4512.
29. Onoe Y, Miyaura C, Ito M, Ohta H, Nozawa S & Suda T 2000 Comparative effects of estrogen and raloxifene on B lymphopoiesis and bone loss induced by sex steroid deficiency in mice. Journal of Bone and Mineral Research 15 541-549.
30. Ostensen M 1999 Sex hormones and pregnancy in rheumatoid arthritis and systemic lupus erythematosus. Annals of the New York Academy of Sciences 876 131-143; discussion 44.
31. Pacifici R 1996 Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis. Journal of Bone and Mineral Research 8 1043-1051.
32. Pike AC, Brzozowski AM, Hubbard RE, Bonn T, Thorsell AG, Engstrom O, Ljunggren J, Gustafsson JA & Carlquist M 1999 Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist. EMBO Journal 18 4608-4618.
33. Rijhsinghani AG, Thompson K, Bhatia SK & Waldschmidt TJ 1996 Estrogen blocks early T cell development in the thymus. American Journal of Reproductive Immunology 36 269-277.
34. Roggia C, Gao Y, Cenci S, Weitzmann MN, Toraldo G, Isaia G & Pacifici R 2001 Up-regulation of TNT-producing T cells in the bone marrow: a key mechanism by which estrogen deficiency induces bone loss in vivo. PNAS 98 13960-13965.
35. Samuels A, Perry MJ & Tobias JH 1999 High-dose estrogen induces de novo medullary bone formation in female mice. Journal of Bone and Mineral Research 14 178-186.
36. Sato M, Kim J, Short LL, Slemenda CW & Bryant HU 1995 Longitudinal and cross-sectional analysis of raloxifene effects on tibiae from ovariectomized aged rats. Journal of Pharmacology and Experimental Therapeutics 272 1252-1259.
37. Sato M, Rippy MK & Bryant HU 1996 Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats. FASEB Journal 10 905-912.
38. Sato T, Shibata T, Ikeda K & Watanabe K 2001 Generation of bone-resorbing osteoclasts from B220+ cells: its role in accelerated osteoclastogenesis due to estrogen deficiency. Journal of Bone and Mineral Research 16 2215-2221.
39. Stoica A, Saceda M, Fakhro A, Joyner M & Martin MB 2000 Role of insulin-like growth factor-I in regulating estrogen receptor-alpha gene expression. Journal of Cellular Biochemistry 76 605-614.
40. Vidal O, Kindblom LG & Ohlsson C 1999 Expression and localization of estrogen receptor-beta in murine and human bone. Journal of Bone and Mineral Research 14 923-929.
41. Vidal O, Lindberg M, Hollberg K, Baylink DJ, Andersson G, Lubahn DB, Mohan S, Gustafsson JA & Ohlsson C 2000 Estrogen receptor specificity in the regulation of skeletal changes in male mice. PNAS 97 5474-5479.